Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?
Prof. Neil Poulter discusses lessons that can be drawn from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.
Video navigation menu
- The association between glucose levels and CV outcomes 00:30
- Novel diabetes drugs prevent CV events 01:37
- Breaking down the details and results of GLP-1RAs CVOTs 03:27
- How do some GLP-1RAs give CV benefit? 05:49
- Subgroep analyses 08:27
- SUmmary & conclusions 12:06
This lecture by prof. John E Deanfield was part of a CME-accredited symposium "Diabetes, Cardiology & Novel Therapeutic Approaches" held during WCC 2018 in Dubai.
Prof. Neil Poulter, FMedSci, cardiologist, Faculty of Medicine, National Heart & Lung Institute; Professor of Preventive Cardiovascular Medicine, Imperial College London, United Kingdom, Member of the Executive Board and President Elect of the International Society of Hypertension
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Funding for this educational program was provided by an unrestricted educational grant from Novo Nordisk.